Over-expression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells
Related Experiment Video
Updated: Jun 17, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Lara Pickel1, Takaya Matsuzuka1, Chiyo Doi1
1Department of Anatomy & Physiology, Kansas State University College of Veterinary Medicine, Manhattan, KS 66506, USA.
Abstract:
The endogenous angiotensin II (Ang II) type 2 receptor (AT 2) has been shown to mediate apoptosis in cardiovascular tissues. Thus, the aim of this study was to explore the anti-cancer effect of AT 2 over-expression on lung adenocarcinoma cells in vitro using adenoviral (Ad), FuGENE, and nanoparticle vectors. All three gene transfection methods efficiently transfected AT 2 cDNA into lung cancer cells but caused minimal gene transfection in normal lung epithelial cells. Ad-AT 2 significantly attenuated multiple human lung cancer cell growth (A549 and H358) as compared to the control viral vector, Ad-LacZ, when cell viability was examined by direct cell count. Examination of annexin V by flow cytometry revealed the activation of the apoptotic pathway via AT 2 over-expression. Western Blot analysis confirmed the activation of caspase-3. Similarly, poly (lactide-co-glycolic acid) (PLGA) biodegradable nanoparticles encapsulated AT 2 plasmid DNA were shown to be effectively taken up into the lung cancer cell. Nanoparticle-based AT 2 gene transfection markedly increased AT 2 expression and resultant cell death in A549 cells. These results indicate that AT 2 over-expression effectively attenuates growth of lung adenocarcinoma cells through intrinsic apoptosis. Our results also suggest that PLGA nanoparticles can be used as an efficient gene delivery vector for lung adenocarcinoma targeted therapy.
Insights
Over-expressing the angiotensin II type 2 receptor (AT2) in lung adenocarcinoma cells triggers apoptosis, inhibiting cancer cell growth. Biodegradable nanoparticles show promise for targeted AT2 gene therapy in lung cancer.
Area of Science:
- Molecular Biology
- Oncology
- Biotechnology
Background:
- The angiotensin II type 2 receptor (AT2) is known to induce apoptosis in cardiovascular tissues.
- Investigating AT2 receptor's role in cancer offers potential therapeutic strategies.
Purpose of the Study:
- To explore the anti-cancer effects of AT2 receptor over-expression in lung adenocarcinoma cells.
- To evaluate adenoviral, FuGENE, and nanoparticle vectors for AT2 gene delivery.
Main Methods:
- Gene transfection using adenoviral (Ad), FuGENE, and poly (lactide-co-glycolic acid) (PLGA) nanoparticle vectors.
- Assessing cell viability via direct cell count and apoptosis via flow cytometry (annexin V).
- Confirming apoptosis pathway activation using Western Blot analysis for caspase-3.
Main Results:
- All tested vectors efficiently transfected AT2 cDNA into lung cancer cells with minimal impact on normal cells.
- Ad-AT2 significantly reduced lung cancer cell growth (A549, H358) compared to Ad-LacZ.
- AT2 over-expression activated apoptosis, confirmed by annexin V staining and caspase-3 activation.
- PLGA nanoparticles effectively delivered AT2 plasmid DNA, increasing AT2 expression and cell death in A549 cells.
Conclusions:
- AT2 receptor over-expression effectively inhibits lung adenocarcinoma cell growth by inducing intrinsic apoptosis.
- PLGA nanoparticles represent a viable and efficient gene delivery vector for targeted lung adenocarcinoma therapy.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Regulation of Angiogenesis and Blood Supply

